Copyright
©The Author(s) 2020.
World J Gastrointest Pharmacol Ther. Jun 9, 2020; 11(2): 17-24
Published online Jun 9, 2020. doi: 10.4292/wjgpt.v11.i2.17
Published online Jun 9, 2020. doi: 10.4292/wjgpt.v11.i2.17
Table 2 Acromegaly abdominal symptoms and medicine use
| Controls (n = 200) | Acromegaly patients (n = 50) | P value (Fisher’s exact test) | ||
| Gastrointestinal symptoms | 32 (16%) | 46 (92%) | ||
| Abdominal pain | 19 (9.5%) | 11(22%) | 0.4905 | |
| Diarrhoea | 8 (4%) | 4 (8%) | 0.2652 | |
| Constipation | 15 (7.5%) | 34 (68%) | < 0.00001b | |
| Medicines | ||||
| Regular use of anti-secretory (PPI/H2RA)/antacids | 11 (6.5%) | 31 (62%) | < 0.00001b | |
| Regular use of laxatives | 6 (3%) | 46 (92%) | < 0.00001b | |
| Regular use of opioid analgesics | 11 (6.5%) | 2 (4%) | Not statistically significant | |
| Somatostatin analogues | - | 37 (74%) |
- Citation: Inayet N, Hayat J, Bano G, Poullis A. Gastrointestinal symptoms in acromegaly: A case control study. World J Gastrointest Pharmacol Ther 2020; 11(2): 17-24
- URL: https://www.wjgnet.com/2150-5349/full/v11/i2/17.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v11.i2.17